Last reviewed · How we verify

NCT07065253

CHOICE KERGUELEN 1: Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands: Inclusion of Volunteers Before Departure to the Kerguelen Islands

Completed Last updated 5 December 2025
What this trial tests

trial testing blood ponction in Human Health in Extreme Conditions in 9 participants. Completed in 25 September 2025.

Timeline
25 September 2025
Primary endpoint
25 September 2025
25 September 2025

Quick facts

Lead sponsorUniversity Hospital, Angers
StatusCompleted
Study typeOBSERVATIONAL
Enrollment9
Start date25 September 2025
Primary completion25 September 2025
Estimated completion25 September 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Angers

Who can join

18 and older, any sex, with Human Health in Extreme Conditions. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system. These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions. To help fill this gap, the CHOICE Kerguelen 1 study will recrut a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen 1 study is conducted in collaboration with the French Polar Institute (IPEV).The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers before they leave for the island, to have baseline medical state and baseline biological samples. These samples will integrate in to healthy volunteer biobank of CHU Angers, a type of biological archive that provided control samples for CHOICE Kerguelen 2 - a clinical study relating to follow-up of volunteers during civic service on the Kerguelen Islands

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of blood ponction

Trials testing the same drug.

Other recruiting trials for Human Health in Extreme Conditions

Currently open trials in the same condition.

Other University Hospital, Angers trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065253.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing